Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 30:3:106.
doi: 10.3389/fonc.2013.00106. eCollection 2013.

Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives

Chiara F Magnani  1 , Sarah Tettamanti, Francesca Maltese, Nice Turazzi, Andrea Biondi, Ettore Biagi
Affiliations

Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives

Chiara F Magnani et al. Front Oncol. .

Abstract

Despite the survival of pediatric patients affected by hematological malignancies being improved in the last 20 years by chemotherapy and hematopoietic stem cell transplantation, a significant amount of patients still relapses. Treatment intensification is limited by toxic side effects and is constrained by the plateau of efficacy, while the pipeline of new chemotherapeutic drugs is running short. Therefore, novel therapeutic strategies are essential and researchers around the world are testing in clinical trials immune and gene-therapy approaches as second-line treatments. The aim of this review is to give a glance at these novel promising strategies of advanced medicine in the field of pediatric leukemias. Results from clinical protocols using new targeted "smart" drugs, immunotherapy, and gene therapy are summarized, and important considerations regarding the combination of these novel approaches with standard treatments to promote safe and long-term cure are discussed.

Keywords: adoptive immunotherapy; advanced therapy; chimeric antigen receptor; gene therapy; novel drugs; pediatric leukemia.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Acharya S., Sahoo S. K. (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 63, 170–18310.1016/j.addr.2010.10.008 - DOI - PubMed
    1. Angiolillo A. L., Yu A. L., Reaman G., Ingle A. M., Secola R., Adamson P. C. (2009). A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children’s Oncology Group report. Pediatr. Blood Cancer 53, 978–98310.1002/pbc.22209 - DOI - PMC - PubMed
    1. Aplenc R., Blaney S. M., Strauss L. C., Balis F. M., Shusterman S., Ingle A. M., et al. (2011). Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children’s oncology group phase I consortium. J. Clin. Oncol. 29, 839–84410.1200/JCO.2010.30.7231 - DOI - PMC - PubMed
    1. Arora A., Scholar E. M. (2005). Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971–97910.1124/jpet.105.084145 - DOI - PubMed
    1. Cieri N., Camisa B., Cocchiarella F., Forcato M., Oliveira G., Provasi E., et al. (2013). IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573–58410.1182/blood-2012-05-431718 - DOI - PubMed